UK Community Advisory Board (UK-CAB)

UK-CAB 28 – Late presenters

Friday 30 January 2009

At the MRC Clinical Trials Unit, 222 Euston Road, London, NW1


09.45-10.00 Coffee, registration and expenses
10.00-10.15 Welcome and announcements updates: BHIVA Rep, SG membership
10.15-10.30 Brief look at use of the UKCAB membership forum – Matthew Williams
10.30-10.45 “Late PresentersBMS/Gilead patient education programme feedback – Michael Marr
10.45-11.00 Break
11.00-11.15 Conference feedback: HIV9
11.15-12.00 Immunology: a rough guide – Dr Adrian Palfreeman, MRC Clinical Trials Unit
12.00-12.30 New MRC HIV Clinical trials –
12.30-14.00 Lunch
14.00-15.30 Company meeting: Tibotec
15.00-15.45 Break
15.45-16.00 UK-CAB AOB
16.00 Close

Background Reading

TRAINING: Immunolgy introduction

Sections 1.5 to 1.9 from this online manual

The sections cover the basics about the organs of the body, the immune system and how HIV interacts with the immune system. It also covers CD4 counts and how to interpret CD4 results and how HIV progresses in different people.

IL-2 studies

IL-2 provides quick ‘AIDS rescue’, but effect does not always last

This article looks at IL2 and how it can be used to boost CD4 counts and how long this may be of benefit. Some of the side effects of LI2 are also discussed.



Darunavir European license extended to all treatment-experienced

Darunavir is comparable to lopinavir in treatment-naive patients


Etravirine overview including comment on drug interaction

Who can use etravirine: understanding etravirine susceptibility: new weighted genotype score and phenotypic cut-offs

Rilpivirine (TMC-278)

Next generation first-line NNRTI, rilpivirine (TMC278) potent; lowest dose better-tolerated than efavirenz at 96 weeks

Financial support

The UK-CAB receives unrestricted funding from some pharmaceutical companies towards the direct costs of holding four meetings each year. This funding supports the travel and accommodation costs for members to attend from outside London, plus the cost of catering.

The content, programme and agenda for meetings is decided by the UK-CAB steering group in consultation with the wider membership. Funding is unconnected to meeting content.

We believe that manufacturers who currently develop and market medicines have a responsibility to actively engage with advocacy organisations and that HIV positive people and their advocates should be able to directly question manufacturers about the safety and efficacy of their products and proposals for future research.

For a list of companies that support the UK-CAB please see the “about us” page.